Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: A systematic review and meta-analysis

Li Liu¹, Yi-Dan Yan¹, Fang-Hong Shi¹, Hou-Wen Lin¹,², Zhi-Chun Gu¹ and Jia Li³*

¹Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²School of Medicine, Tongji University, Shanghai, China, ³Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: We aim to evaluate the efficacy and tolerability of Janus kinase inhibitors (JAKi) as monotherapy and in combination with methotrexate (MTX) in active rheumatoid arthritis (RA).

Methods: Medline, EMBASE, and Cochrane Library were systematically searched to identify relevant randomized controlled trials (RCTs). Pooled analysis was conducted using random-effects model, along with the risk difference (RD) and 95% confidence intervals (CIs).

Results: Three RCTs, including 2,290 patients, were included. JAKi (tofacitinib, baricitinib, and filgotinib) plus MTX displayed a higher proportion of patients meeting the American College of Rheumatology (ACR) criteria than JAKi alone at week 52 (ACR20 RD 0.032; 95% CI −0.027 to 0.091; ACR50 RD 0.050; 95% CI 0.003 to 0.097; ACR70 RD 0.056; 95% CI 0.012 to 0.100). Similar results were observed for ACR20/50/70 at week 24. No significant difference was found between two regimens for the proportion of patients achieving Health Assessment Questionnaire disability index (HAQ-DI) improvement ≥ 0.22 at weeks 24 and 52. Regarding low disease activity and remission achievement, JAKi in combination with MTX, contributed higher response rates than JAKi alone at weeks 24 and 52. Compared with JAKi monotherapy, combination therapy had a higher risks of treatment-emergent adverse events (TEAEs) and adverse events (AEs) leading to study discontinuation.

Conclusion: JAKi combined with MTX demonstrated superiority to JAKi monotherapy in terms of ACR responses, low disease activity and remission achievement. The two regimens presented comparable physical functioning measured by HAQ-DI improvement and similar tolerability, except for high risks of TEAEs and AEs leading to study discontinuation in combination therapy.
Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by painful, swollen joints and progressive bone erosion that affects physical functioning and quality of life (1). The therapeutic landscape of RA has been rapidly changing in recent years. Besides conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) and biologic DMARDs (bDMARDs), a new class of targeted synthetic DMARDs (tsDMARDs), represented by Janus kinase inhibitors (JAKi), has been introduced in the clinical practice for RA treatment. The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) recommends starting treatment for RA with csDMARDs, preferably MTX (2, 3). JAKi could be added to csDMARDs if the treatment target is not achieved with the initial strategy, but is complicated by poor prognostic factors (2). Pivotal randomized controlled trials (RCTs) have proven the favorable efficacy and safety of JAKi combined with csDMARDs in RA, especially in combination with MTX (4–9).

The Janus kinase signal transducer and activator of transcription (JAK/STAT) pathway, which is implicated in the pathogenesis of RA, involves four members: JAK1, JAK2, JAK3, and TYK2 (10, 11). JAKi, as small molecules, inhibit the JAK/STAT pathway and block intracellular signaling mediated by multitudinous proinflammatory cytokines and other molecules, contributing to RA improvement (12). Currently, there are several licensed JAKi for RA treatment. Tofacitinib, a first-generation JAKi with predominant JAK1/JAK3 selectivity, was approved for RA treatment by the Food and Drug Administration in 2012 (13). Other licensed JAKi include baricitinib, which selectively inhibits JAK1/JAK2, and upadacitinib and filgotinib, which selectively inhibit JAK1 (14). JAKi are generally tolerated well with an acceptable safety profile; however, there are some specific safety concerns, such as herpes zoster infection, malignancy, and venous thromboembolism (12, 15).

Although established recommendations suggest dual therapy (JAKi plus MTX or other csDMARDs), patients under JAKi monotherapy have been estimated to account for approximately one-third in real-world practice due to intolerance of, or noncompliance, with MTX (16, 17). Published articles on tofacitinib indicated that based on clinical experience, JAKi monotherapy was suitable for approximately 60–70% of patients with RA and offered several practical advantages like reduction in medical expense, reduced csDMARDs-related adverse events and convenience of use (18). Previous RCTs, namely ORAL Solo (19), ORAL Start (20), RA-BEGIN (21), and SELECT-MONOTHERAPY (22), also validated the efficacy of JAKi monotherapy in RA treatment, with acceptable tolerability.

Currently, there is controversy over whether JAKi monotherapy has comparable efficacy and safety to JAKi plus MTX. However, comparisons of the two therapeutic regimens for the treatment of RA are rare. A phase 3b/4, double-blind, head-to-head RCT (ORAL Strategy) assessed the comparative efficacy of tofacitinib as a monotherapy or with MTX. The results were defined as statistically inconclusive because tofacitinib alone did not show non-inferiority to tofacitinib and MTX in the ACR50 response rate at six months (23). In contrast, the RA-BEGIN trial indicated that the efficacy of baricitinib monotherapy (ACR20 response rate at week 24) was similar to that of the combination with MTX; however, the study design lacked statistical comparisons between the concerned arms (21). As a result, we performed a meta-analysis in light of available data from recent RCTs to compare the efficacy and tolerability of JAKi as monotherapy and as combination therapy with MTX in the treatment of patients with active RA. We present the following article in accordance with the PRISMA reporting checklist.

Methods

This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement (24), and a prior protocol for this study was registered at the International Prospective Register of Systematic Reviews (PROSPERO: CRD42021288907 URL: https://www.crd.york.ac.uk/PROSPERO/#recordDetails).

Literature search

We systematically searched Medline, EMBASE, and Cochrane Library to identify potentially eligible studies until May 17, 2022. Details of the study search process are presented in Supplementary
Table 1. ClinicalTrials.gov was also searched to identify unpublished trials. The search was restricted to RCTs, human participants, and English publications. Cited references, meta-analyses, and reviews were reviewed to identify additional studies.

**Study selection**

To determine study eligibility, two reviewers (LL and Y-DY) independently screened all titles and abstracts, and all papers were assessed based on the entry criteria. Any disagreements were resolved through discussion with the corresponding authors (JL, Z-CG and H-WL). Studies meeting the following criteria were included: (1) inclusion of patients with RA according to a standardized diagnostic classification system (ACR 1987 or EULAR/ACR 2010 criteria) (25, 26); (2) original reports of phase II and phase III RCTs; (3) JAKi therapy as monotherapy and in combination with MTX; and (4) available data on the efficacy and safety endpoints. The exclusion criteria for studies were: conference abstracts, reviews, letters, editorials, case reports, observation studies, long-term extension studies and post hoc analyses.

**Outcomes of interest**

To ensure that sufficient data were used in the meta-analysis and to reduce the influence of confounding factors, the primary efficacy outcomes were regarded as the proportions at week 52 of patients achieving an ACR20/50/70 response, which means 20%/50%/70% improvement, respectively, in the ACR criteria (27); the proportion of patients sustaining low disease activity (as defined by Disease Activity Score in 28 joints, erythrocyte sedimentation rate or C-reactive protein [DAS28-4 (ESR/CRP)] ≤ 3.2, Simplified Disease Activity Index [SDAI] ≤ 11, Clinical Disease Activity Index [CDAI] ≤ 10); the proportion of patients attaining remission (as defined by DAS28-4 (ESR/CRP) < 2.6, SDAI ≤ 3.3, CDAI ≤ 2.8) at week 52; and the proportion of patients with Health Assessment Questionnaire disability index (HAQ-DI) improvement ≥ 0.22 at week 52. Secondary efficacy outcomes included the measures obtained at week 24. The safety outcomes were incidence at week 52 of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events (AEs) leading to study discontinuation, deaths, serious infections, herpes zoster infection, opportunistic infections, malignancy, venous thromboembolism (VTE), and major adverse cardiovascular events (MACE).

**Data extraction and quality assessment**

Data were extracted into a pre-specified electronic form, including study characteristics (study name, NCT number, publication time, and duration of interventions), patient demographics (mean age, duration of RA, disease activity status), and reported outcomes of interest. Two independent reviewers (LL and Y-DY) performed the methodological quality assessment using the Cochrane Collaboration Risk of Bias Tool (28). Any dispute was resolved by consensus or consultation with the corresponding authors (JL, Z-CG and H-WL).

**Statistical analyses**

All statistical analyses were performed using Stata version 13.1 (Stata Corporation, College Station, Texas, USA). Meta-analysis estimates of the studies were derived and presented as forest plots. Risk difference (RD) and 95% confidence intervals (CIs) were calculated by applying a Mantel-Haenszel random-effects model. An RD more than 0 indicated a higher trend in JAKi combination therapy than in monotherapy. The I² test was used to test the heterogeneity among the studies (> 50% considered significant heterogeneity) (29). Statistical significance was set at $P < 0.05$.

**Results**

**Study selection and characteristics**

Among 2,340 records revealed by the literature search, 50 articles were of potential interest. We excluded 47 articles after checking the full text. Detailed reasons were displayed in Supplementary Table 2. Further investigation resulted in three RCTs comprising 2,290 RA patients meeting the inclusion criteria (21, 23, 30), with 1,007 patients in the JAKi plus MTX combination arm and 753 patients in the JAKi monotherapy arm (Figure 1). All studies were registered on clinicaltrials.gov and we obtained the complete results. Among the included trials, one trial employed tofacitinib, one trial employed baricitinib, and the remaining one used filgotinib. Table 1 presents the characteristics of the included studies. Patients with RA who had no or limited prior exposure to MTX and who had an inadequate response to MTX were included. The study duration was 52 weeks (one year for one study). MTX was administered orally once weekly, and dose of MTX ranging from 10 mg to 25 mg. The mean age ranged from 50.1 years to 53.2 years. The average disease duration of RA was 3.1 years in the JAKi combination group and 4.2 years in the JAKi monotherapy group. The mean SDAI and CDAI were 41.8, 39.7 in the combination group and 41.2, 39.3 in the JAKi monotherapy group, respectively.

**Risk of bias**

Table 2 presents the quality assessment results of included RCTs. The included RCTs satisfied four tool items (random sequence generation, blinding of participants and personnel,
incomplete outcome data, and selective reporting). One study did not satisfy the blinding of outcome assessment item and was judged as moderate risk bias. Regarding allocation concealment, one study did not present the allocation concealment method and was evaluated as having an unclear risk bias. Overall, one study was judged to have a moderate risk of bias, and the rest were considered to have a low risk of bias.

Primary efficacy outcomes

The proportions of patients who achieved ACR response, HAQ-DI improvement ≥ 0.22, low disease activity, and remission were used to assess the efficacy of JAKi plus MTX versus JAKi alone. Forest plots of efficacy outcomes are shown in Figure 2A. In general, JAKi combination therapy was superior to

TABLE 1 Characteristics of included randomized controlled trials.

| Study          | ORAL Strategy | RA-BEGIN | FINCH |
|----------------|---------------|----------|-------|
| Study year     | 2017          | 2017     | 2021  |
| NCT number     | NCT02187055   | NCT01711359 | NCT02886728 |
| Study duration | 1 year        | 52 weeks | 52 weeks |
| Mean age (years) | 50.1        | 50.3     | 53.2  |
| Phase of study | IIIb/IV       | III      | III   |
| Study location | worldwide     | worldwide | worldwide |
| Included arms  | Tofa 5 mg     | Tofa 5 mg + MTX<sup>a</sup> | Bar 4 mg + MTX<sup>b</sup> |
| No. of patients| 384           | 376      | 159   |
| Duration of disease (years) | 6.1          | 5.4      | 1.9   |
| DAS28-4 (ESR)  | 6.5           | 6.6      | 6.6   |
| DAS28-4 (CRP)  | 5.7           | 5.8      | 5.9   |
| SDAI           | 40.2          | 41.6     | 43    |
| CDAI           | 38.6          | 39.7     | 40    |
| HAQ-DI         | 1.6           | 1.6      | 1.6   |
| Race (%)       |               |          |       |
| White          | 77            | 76       | N     |
| Black or African American | 3           | 5       | N     |
| Asian          | 11            | 10       | N     |
| Others         | 9             | 9        | N     |

Data are mean; Tofa, Tofacitinib; Bar, Baricitinib; Filg, Filgotinib; No., number; N, unknown.
<sup>a</sup>MTX was administered orally once weekly, starting with 10 mg/week and escalating to 15 mg at week 4 and 20 mg at week 8.
<sup>b</sup>MTX was initiated at 10 mg/week and, if tolerated, increased to 20 mg/week by week 8.
<sup>c</sup>MTX was administrated with a stable dose of 15-25 mg per week.
JAKi monotherapy. The heterogeneity of the included studies was relatively low ($I^2 < 50\%$ for each outcome).

ACR and HAQ-DI

Viewed separately, at week 52, JAKi plus MTX was associated with a comparable ACR20 response rate to JAKi alone (RD 0.032; 95% CI −0.027 to 0.091). The proportion of patients achieving ACR20 was 72.69% (732/1007) in the combination group and 67.74% (510/753) in the JAKi group (Supplementary Table 3). For ACR50 and ACR70, patients receiving JAKi and MTX (ACR50: 56.72%; ACR70: 40.40%) attained a higher response rate compared with those receiving JAKi alone (ACR50: 49.26%; ACR70: 32.26%), with RD 0.050 (95% CI: 0.003 to 0.097) and 0.056 (95% CI: 0.012 to 0.100), respectively. Notably, no significant difference between the two regimens was found for the proportion of patients achieving

**TABLE 2** Quality assessment results of included randomized controlled trials.

| Study | ORAL Strategy | RA-BEGIN | FINCH |
|-------|---------------|----------|-------|
| Random sequence generation | L | L | L |
| Allocation concealment | L | U | L |
| Blinding of participants and personnel | L | L | L |
| Blinding of outcome assessment | M | L | L |
| Incomplete outcome data | L | L | L |
| Selective reporting | L | L | L |

L, low risk; M, moderate risk; U, unclear risk.

One study did not satisfy the item of blinding of outcome assessment and was judged as moderate risk bias. With regards to allocation concealment, one study did not present the allocation concealment method and was evaluated as unclear risk bias. Overall, one study was judged to have a moderate risk of bias and the remaining two were considered to have a low risk of bias.
HAQ-DI improvement ≥ 0.22 (RD 0.001; 95% CI −0.024 to 0.026).

Low disease activity and remission achievement

Regarding low disease activity at week 52, JAKi plus MTX regimen group presented a relatively higher percentage of patients achieving SDAI ≤ 11 (54.15%) and CDAI ≤ 10 (54.31%) than the JAKi monotherapy group (SDAI ≤ 11: 48.80%; CDAI ≤ 10: 49.17%), indicating more significant improvement in SDAI ≤ 11 (RD 0.043; 95% CI −0.015 to 0.101) and CDAI ≤ 10 (RD 0.042; 95% CI −0.016 to 0.100). Furthermore, significant differences were observed in the proportions of patients attaining SDAI ≤ 11 (RD 0.043; 95% CI 0.002 to 0.107) and CDAI ≤ 10 (RD 0.049; 95% CI 0.003 to 0.095) between the two groups. Regarding the percentage of patients attaining remission at week 52, we observed higher response rates among those treated with combination therapy compared with JAKi monotherapy, with RD 0.050 (95% CI 0.008 to 0.092) for SDAI ≤ 3.3, RD 0.054 (95% CI 0.015 to 0.093) for CDAI ≤ 2.8, RD 0.043 (95% CI 0.001 to 0.085) for DAS28-4 (ESR) < 3.2, and RD 0.063 (95% CI 0.018 to 0.108) for DAS28-4 (CRP) < 2.6.

Secondary efficacy outcomes

The secondary endpoints at week 24 remained consistent with the primary outcomes, as presented in Figure 2B. Compared with JAKi monotherapy, patients treated with combination therapy at week 24 yielded higher percentages of response rates for ACR20 (RD 0.047; 95% CI 0.006 to 0.088) and ACR50 (RD 0.054; 95% CI 0.007 to 0.101). For ACR70, JAKi with MTX resulted in high response rates, although there was no significant difference between the two groups (RD 0.039; 95% CI −0.010 to 0.089). For the proportion of patients achieving HAQ-DI improvement ≥ 0.22 at week 24, patients under JAKi plus MTX or JAKi alone showed a similar trend (RD 0.000; 95% CI −0.025 to 0.024). The proportions of patients achieving low disease activity and remission was largely unchanged from week 24 to week 52.

Safety outcomes

The meta-analysis assessed the tolerability of JAKi monotherapy and combination therapy in patients with active RA (Figure 3). The incidence of TEAEs was 59.19% (596/1007) in the JAKi plus MTX group and 47.41% (357/753) in the JAKi group (Supplementary Table 4), indicating a higher risk of TEAEs within combination therapy versus JAKi monotherapy (RD 0.056; 95% CI 0.014 to 0.099). In addition, more patients reported AEs leading to study discontinuation in JAKi plus MTX group (7.65%) than in JAKi alone group (4.91%), with RD 0.032 (95% CI 0.007 to 0.057). However, the incidence of SAEs and deaths were similar between the two treatment groups (SAEs: RD −0.014; 95% CI −0.040 to 0.012 and deaths: RD 0.000; 95% CI −0.000 to 0.007). For adverse events of special interest, low frequencies were observed for both treatment groups in terms of serious infections, herpes zoster infection, opportunistic infections, malignancy, VTE, and MACE. The risk for serious infections was not higher in the combination group than in the JAKi group (RD 0.000; 95% CI −0.022 to 0.023). Both JAKi combination and JAKi monotherapy groups displayed similar risks of herpes zoster infection (RD 0.004; 95% CI −0.009 to 0.016), opportunistic infections (RD 0.000; 95% CI −0.006 to 0.006), malignancy (RD 0.002; 95% CI −0.010 to 0.014), VTE (RD 0.000; 95% CI −0.005 to 0.005), and MACE (RD −0.001; 95% CI −0.005 to 0.004).

![Safety outcomes](image.png)
Discussion

To the best of our knowledge, the present study is the first to directly evaluate the effectiveness and safety of Janus kinase inhibitors treatment with or without MTX in patients with active RA. The JAKi plus MTX regimen showed superiority in achieving ACR response, HAQ-DI improvement, low disease activity, and remission versus JAKi alone. Furthermore, the JAKi combination therapy was associated with similar tolerability compared to monotherapy, except for TEAEs and AEs leading to study discontinuation.

According to the present recommendations for RA treatment, JAKi should be adopted as an add-on strategy to the ongoing csDMARD regimen, mostly MTX (2, 3). However, new evidence has demonstrated that JAKi with or without MTX presented favorable efficacy and acceptable safety compared with placebo or MTX. A meta-analysis identified that compared with placebo, JAKi monotherapy or combination therapy improved RA control as determined by ACR20 (risk ratio: 2.03) and HAQ-DI scores (mean differences: −0.31) (31). Concerning JAKi monotherapy, different JAK inhibitors led to statistically significant improvement in ACR20 response rate compared with placebo (odds ratio: from 2.03 to 17.24) (32, 33). Furthermore, the ACR50 and ACR70 response rates showed a similar trend to the ACR20 criteria. Compared with MTX, JAKi monotherapy also displayed superiority in RA improvement (20, 21). In terms of combination therapy, several RCTs had suggested that JAKi combined with MTX was preferred over MTX alone for different efficacy endpoints, including ACR response criteria and improvement in physical functioning (4, 5, 9, 21, 34, 35). Moreover, long-term extension studies determined that JAKi, in general, showed a consistent safety profile as monotherapy or combination therapy (36, 37).

However, in clinical practice, adherence to MTX is relatively low. A cross-sectional survey showed that forgetting to take MTX, thinking it was not needed when they felt well, and the concern about the long-term safety of MTX, contributed to the nonadherence to MTX (38). Gastrointestinal events are the most commonly reported AEs (pooled prevalence: 32.7%) in patients with RA starting MTX (39). Furthermore, the reluctance of patients to take multiple drugs to manage their disease is due to fear of drug-drug interactions or inadequate pharmacological clearance in elderly patients (40). Therefore, there is an urgent need for evidence to clarify whether JAKi monotherapy regimens could replace combination regimens to avoid inadequately controlled disease in some RA patients under JAKi monotherapy.

However, there have been few comparisons between JAKi monotherapy and combination therapy. A network meta-analysis demonstrated that several novel DMARDs (including tocilizumab, anti-tumor necrosis factor, and tofacitinib) showed different levels of efficacy as monotherapy and in combination with MTX (16). For example, tocilizumab combined with MTX displayed similar ACR responses versus tocilizumab alone, whereas anti-tumor necrosis factor or tofacitinib showed greater ACR response rates in combination regimen versus monotherapy. However, this study involved only a single JAKi (tofacitinib) and less effective evaluation indexes. Furthermore, it did not compare the safety profiles of JAKi monotherapy and combination therapy. In 2018, a systematic review assessing the efficacy of biologics and JAKi reported the superiority of bDMARDs/tsDMARDs + csDMARD to bDMARDs/tsDMARDs monotherapy, without any individualized or fully quantified results for JAKi (17). Similarly, no safety outcomes were reported for the different treatment regimens.

Given the above limitations and uncertainty, it is necessary to rigorously assess the efficacy and safety of JAKi with or without MTX. As a result, we performed a systematic review and meta-analysis based on evidence from RCTs to comprehensively evaluate this issue using multiple indexes. Better treatment outcomes are usually achieved with combination therapy, and this was validated by our analysis. We determined that JAKi combination therapy with MTX is likely to be more effective than JAKi treatment alone. Of importance, for each outcome analyzed, efficacy was basically consistent at week 24 and week 52 regardless of whether JAKi was administered with or without MTX.

Clinically meaningful improvements in RA manifestations as measured by ACR response rates were maintained over time in patients who received JAKi as monotherapy or combination therapy. The results of the present analysis were in line with those of a previous conducted network meta-analysis, in which greater ACR20/50/70 responses were observed with tofacitinib plus MTX than with tofacitinib monotherapy at week 24 (the probability that tofacitinib + MTX was better than tofacitinib at attaining ACR 20/50/70 responses was 83%, 84%, and 94%, respectively) (16). Although ACR response is a composite measure that captures improvement in tender and swollen joint, achieving remission or low disease activity, as well as improvement in physical functioning measured by HAQ-DI, are the main goals of RA treatment (2, 3). Our analysis demonstrated that in patients with active RA, JAKi, in combination with MTX, was more prone to attain remission and low disease activity than JAKi monotherapy, although most indexes were associated with a favorable trend of response rate without a significant difference. Regarding the HAQ-DI improvement, interestingly, JAKi monotherapy displayed comparable efficacy to combination therapy at week 24 and week 52. A pooled analysis of tofacitinib showed consistent results and was maintained until month 72, albeit with a loss of direct comparison between monotherapy and combination therapy (41).

As a new targeted drug class, JAKi may affect broader pathways beyond those being targeted, so evidence of the safety profile of JAKi still needs careful investigation and accumulation in patients with RA (12, 15). The incidence of adverse events seems similar to bDMARDs, with infections (42), VTE (43, 44), malignancies (45), and cardiovascular safety (46,
47) being the most concerning adverse events (48). In terms of the safety of JAKi with or without MTX, the frequency of adverse events was comparable between the two regimens, except for TEAEs and AEs leading to study discontinuation. This seems reasonable because of the intolerance and nonadherence to MTX in some patients; therefore, JAKi monotherapy appears to be a preferred treatment option for such patients (17, 38). The results confirm the credibility of our analysis. Regarding adverse events of particular interest (serious infections, malignancy, VTE, MACE, etc.), no meaningful difference was observed between JAKi monotherapy and combination therapy; however, these results should be interpreted with caution because of the limited number of adverse events assessed.

In addition, in our meta-analysis, for the remaining double-arm-zero-events in the included trials, we used risk difference and the Mantel-Haenszel random-effects model to analyze all events in patients because double-arm-zero-events studies are automatically discarded when the Mantel-Haenszel method with odds ratio or risk ratio is utilized (49). Omitting double-arm-zero-events would contribute to inappropriate choices in evidence synthesis, and misleading the healthcare practice; therefore, the Mantel-Haenszel random-effects model along with risk difference would be a favorable choice.

**Strengths and limitations**

Our study offers the first comprehensive and detailed comparative evaluation of the effectiveness of JAKi monotherapy versus combination therapy with MTX based on various effective outcomes (ACR response rate, HAQ-DI improvement, low disease activity, and remission achievement) and follow-up analyses (week 24 and week 52), as well as the safety of the two therapeutic regimens. Although the number of studies included for comparison was too small to generate an absolute conclusion, in contrast to individual studies, our analysis obtained more accurate data by increasing the statistical power and validated the superiority of JAKi combination therapy to monotherapy with comparable tolerability in patients with RA. However, the analysis reported here has several limitations. First, the study covered a minimal number of studies involving only three JAKi agents (tofacitinib, baricitinib, and filgotinib). Other JAKi, such as upadacitinib and peficitinib were not included due to current drug trials (upadacitinib, peficitinib) failing to address the comparison as monotherapy and in combination with MTX. The limited studies made subgroup analysis unavailable, except for effective outcomes by different follow-ups (week 24 and week 52). Specifically, the low frequency of VTE or malignancy was insufficient to determine the safety outcomes of JAKi as monotherapy or combination therapy. Accumulation of evidence of more RCTs about other JAKi in decision-making is needed. Second, the limited number of articles included prevented a full stratification for disease sub-populations of interest, like csDMARDs naïve or csDMARDs-experienced patients. Third, an analysis of approximately one-year RCT data would provide a somewhat limited picture as it is insufficient to determine the long-term durability and tolerability of JAKi monotherapy and combination therapy with MTX. Meanwhile, radiographic progression of RA patients was not assessed. More comparative studies and long-term observational studies are warranted in the future. Furthermore, the results of this meta-analysis were based on evidence from RCTs and may not be generalizable to the broader RA population with heterogeneous characteristics and therapeutic regimens in the real world.

**Conclusion**

Based on a meta-analysis of direct comparisons of RCT data, we found that JAKi, in combination with MTX, demonstrated superiority in ACR responses, low disease activity, and remission achievement, to JAKi monotherapy in active RA treatment. The two regimens presented comparable physical functioning measured by HAQ-DI improvement, along with similar tolerability, except for high risks of TEAEs and AEs leading to study discontinuation in combination therapy. Long-term pharmacovigilance of JAKi as monotherapy and in combination with MTX in RA is warranted.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

**Author contributions**

All authors made substantial contributions to the conception and design of this study. LL and F-HS drafted the manuscript. LL and Y-DY performed the meta-analysis. JL, Z-CG and H-WL revised and approved the final manuscript. All authors contributed to the article and approved the submitted version.

**Funding**

This study was supported by the Clinical Research Innovation and Cultivation Fund of Ren Ji hospital (RJPY-LX-008), Ren Ji Boost Project of National Natural Science Foundation of China (RJTF-JX-001), Research Project of Drug Clinical Comprehensive Evaluation and Drug Treatment Pathway (SHYXH-ZP-2021-001), and Clinical Research Training Project of Renji Hospital (PY2018-III-04).
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.977265/full#supplementary-material

References

1. Sparks JA. Rheumatoid arthritis. Ann Intern Med (2019) 170(1):1c–10c. doi: 10.7326/M18-2510
2. Smolen JS, Landewe RBM, Bijlona JW, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2019 update. Ann Rheumatic Dis (2020) 79(6):685–99. doi: 10.1136/annrheumdis-2020-216655
3. Fraenkli L, Bathon JM, England BR, St Clair Ew, Araszi T, Carandang K, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (2021) 73(7):924–39. doi: 10.1002acr.25496
4. Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New Engl J Med (2017) 376(7):652–62. doi: 10.1056/NEJMoa1608345
5. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Bendia R, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet (London England) (2016) 388(10061):151–60. doi: 10.1016/S0140-6736(15)00736-5
6. Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London England) (2019) 394(10188):2303–12. doi: 10.1016/S0140-6736(18)31211-2
7. Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HS, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann Rheumatic Dis (2021) 80(7):848–57. doi: 10.1136/annrheumdis-2020-208246
8. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheumatic Dis (2017) 76(1):88–95. doi: 10.1136/annrheumdis-2016-210094
9. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New Engl J Med (2012) 367(6):508–19. doi: 10.1056/NEJMoa1112072
10. O’Shea JJ, Laurence A, McNees IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol (2013) 9(3):173–82. doi: 10.1038/nrrheum.2013.7
11. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of jak-STAT signalling in the immune system. Nat Immunol (2017) 18(4):374–84. doi: 10.1038/nim.2016.369
12. Fradjoulis GE, Brock J, Basu N, McNees IB, Siebert S. The role for Jak inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol (2021) 148(4):941–52. doi: 10.1016/j.jaci.2021.08.010
13. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&AppNo=208246
14. Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatol (Oxford England) (2019) 58(6):953–62. doi: 10.1093/rheumatology/key339
15. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheumatic Dis (2021) 80(1):71–87. doi: 10.1136/annrheumdis-2020-218398
16. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Janssen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis. J managed Care specialty Pharm (2015) 21(5):409–23. doi: 10.18553/jmcnp.2015.21.5.409
17. Emery P, Pope Jh, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of monotherapy with biologics and Jak inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther (2018) 35(10):1535–63. doi: 10.1007/s12265-018-0757-2
18. Fleischmann R. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opin pharmacotherapy (2017) 18(14):1525–33. doi: 10.1080/14656566.2017.1370453
19. Fleischmann R, Kremer J, Cuhj J, Schüde-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New Eng J Med (2012) 367(6):495–507. doi: 10.1056/NEJMoa1109071
20. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New Eng J Med (2014) 370(25):2377–86. doi: 10.1056/NEJMoa1404767
21. Fleischmann R, Schell M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol (Hoboken NJ) (2017) 69(3):506–17. doi: 10.1002/art.39553
22. Smolen JS, Pangan AJ, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): A randomised, placebo-controlled, double-blind phase 3 study. Lancet (London England) (2019) 393(10188):2303–11. doi: 10.1016/S0140-6736(19)30419-2
23. Fleischmann R, Myler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet (London England) (2019) 390(10093):457–68. doi: 10.1016/S0140-6736(17)31616-5
24. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Res ed) (2021) 372:n160. doi: 10.1136/bmj.n160
25. Alathea D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO3rd, et al. 2010 rheumatoid arthritis classification criteria: An American college of Rheumatology/European league against rheumatism collaborative initiative. Arthritis rheumatol (2010) 62(9):2569–81. doi: 10.1002/art.27584
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis rheumatol (1988) 31(3):315–24. doi: 10.1002/art.1780310302
27. Felson DT, Anderson JF, Boers M, Bombardier C, Forst D, Goldsmith C, et al. American College of rheumatology. preliminary definition of improvement in rheumatoid arthritis. *Arthritis rheumatism* (1995) 38(6):727–35. doi: 10.1002/1708-880602

28. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. *BMJ (Clinical Res ed)* (2011) 343:d5928. doi: 10.1136/bmj.d5928

29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* (2002) 21(15):1539–58. doi: 10.1002/sim.1186

30. Westhoven R, Rigby WFC, van der Heijde D, Ching DWT, Stohl W, Kay J, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. *Ann Rheumatic Dis* (2021) 80(6):727–38. doi: 10.1136/annrheumdis-2020-219213

31. Wang F, Sun L, Wang S, Davis JMrd, Matteson EL, Murad MH, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis. *Mayo Clinic Proc* (2020) 95(7):1404–19. doi: 10.1016/j.mayocp.2020.01.039

32. Ho Lee Y, Gyu Song G. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis. *J Clin Pharm Ther* (2020) 45(4):674–81. doi: 10.1111/jcpt.13142

33. Lee YH, Song GG. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. *Z für Rheumatologie* (2021) 80(4):379–92. doi: 10.1007/s00393-020-00796-1

34. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. *Ann Internal Med* (2013) 159(4):253–61. doi: 10.7326/0003-4819-159-4-201308200-00006

35. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis rheumatism* (2013) 65(3):559–70. doi: 10.1002/art.37816

36. Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study with patients with rheumatoid arthritis. *J Rheumatol* (2018) 45(1):14–21. doi: 10.3899/jrheum.161161

37. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. *Arthritis Res Ther* (2019) 21(1):89. doi: 10.1186/s13075-019-1866-2

38. Dilledenetti DB, Zhou X, Reynolds M, Ogale S, Best JH. Assessing methotrexate adherence in rheumatoid arthritis: A cross-sectional survey. *Rheumatol Ther* (2015) 2(1):73–84. doi: 10.1007/s40744-015-0011-1

39. Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM. Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: A systematic review. *Rheumatol (Oxford England)* (2021) 66(9):4001–17. doi: 10.1093/rheumatology/keab304

40. Doria A, Zavaglia D. Monotherapy is a relevant option in rheumatoid arthritis treatment: A literature review. *Clin Exp Rheumatol* (2019) 37(5):862–71. Available at: https://www.clinexpther.org/article.asp?id=13054.

41. Fleischmann R, Wollenhaupt J, Takiya L, Maniccia A, Kwock K, Wang L, et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. *RMD Open* (2017) 3(2):e000491. doi: 10.7326/0003-4819-159-4-201308200-00006

42. Bechman K, Subasinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of inductive risk with small molecule JAK inhibitors in rheumatoid arthritis. *Rheumatol (Oxford England)* (2019) 58(10):1755–66. doi: 10.1093/rheumatology/kez087

43. Yates M, Mootoo A, Ada M, Bechman K, Rampes P, Patel V, et al. Venous thromboembolism risk with JAK inhibitors: A meta-analysis. *Arthritis Rheumatol (Hoboken NJ)* (2021) 73(5):779–88. doi: 10.1002/art.41580

44. Setyawan J, Azimia N, Strand V, Yarur A, Friedman M. Reporting of thromboembolic events with JAK inhibitors: Analysis of the FAERS database 2010-2019. *Drug Saf* (2021) 44(8):889–97. doi: 10.1002/ds.40264-021-01812-y

45. Solupuran V, Mohan A, Patel R, Ni R. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. *Auto-Immun Highlights* (2021) 12(1):8. doi: 10.1186/s41317-021-00153-5

46. Xie W, Huang W, Xiao S, Sun X, Fan Y, Zhang Z. Impact of janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. *Ann Rheumatic Dis* (2019) 78(8):1048–54. doi: 10.1136/annrheumdis-2018-214846

47. Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CB, Zhang X, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. *Arthritis Rheumatol* (Hoboken NJ) (2019) 71(7):1042–55. doi: 10.1002/art.40841

48. Viera MC, Zvollichev SH, Jensen JP, Smacichowski B, Speerden D, Wallenstein GV. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: Results from a network meta-analysis. *Clin Ther* (2016) 38(12):2628–41.e2625. doi: 10.1016/j.clinthera.2016.11.004

49. Xu C, Furuya-Kanamori L, Zorzela L, Lin L, Vohra S. A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. *J Clin Epidemiol* (2021) 135:70–8. doi: 10.1016/j.jclinepi.2021.02.012

Liu et al. 10.3389/fimmu.2022.977265

Frontiers in Immunology 10